The Neurotech Investing and Partnering Conference 2013

San Francisco, California
Thursday, May 23, 2013

Location: St. Regis San Francisco Gallery Ballroom 2nd Floor
  Thursday May 23, 2013
 7:00 Breakfast and Registration
 8:00 Welcome: The Global Neurotech Industry 2013
  NeuroInsights provides an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics. 

Casey Lynch, Managing Director, NeuroInsights

 8:30 Investing in Neurotech Panel
  A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Frank Eeckman, Managing Director, Woodside Capital Partners 

Eric Elenko, Partner, Puretech Ventures

Kelly Holman, Managing Director, Genesys Capital

Oleg Nodelman, Founder & Managing Director, EcoR1 Capital

Ilan Zipkin, Senior Investment Director, Takeda Ventures Inc.

9:30 Networking and Refreshment Break
10:00  Alzheimer's and Cognitive Disorders
  As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?  Can earlier or more accurate diagnosis improve outcomes?

Session Chair: Nina Kjellson, General Partner, Interwest Partners

Andrew Blackwell, CSO, Cambridge Cognition

Franz Hefti, CEO, Acumen Pharmaceuticals

Nancy Stagliano, CEO, iPierian


Robert Weisskoff, CEO, EnVivo Pharmaceuticals and Partner, Fidelity Biosciences

Evian Gordon,

 Chairman and Founder

, Brain Resource

11:30 New Developments Chronic and Neuropathic Pain
  Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in chronic and neuropathic pain.

Session Chair: Heath Lukatch, Partner, Novo Ventures

Tom McCarthy, CEO and Managing Director, Spinifex Pharmaceuticals

Jim Schoeneck, CEO, Depomed

Maria Bennett, CEO, SPR Therapeutics

John Allison, VP Research and Development, Myoscience

2:00 Internal and External Research & Development
  What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?

Moderator: Bruce Leuchter, Director Clinical Neuropsychiatry, Weill Cornell & Chairman Click Therapeutics

Erik Bardrum Nielsen, 

Director, Scientific Licensing,


Corporate BD & Strategy,


H. Lundbeck A/S

Guy Seabrook, Neuroscience, California Innovation Center, Janssen Pharmaceutical 

Peter Stebbins, VP New Business Development, Codman and Depuy Mitek, Johnson & Johnson

Shafique Virani, Global Head Neuroscience, Cardiovascular & Metabolism Partnering, Hoffman-La Roche

Networking and Refreshment Break
3:30 Next Generation Psychiatry
  Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market.  What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?

Session Chair: Manuel Lopez Figueroa, Vice President, Bay City Capital

Byron Hewett, CEO, BioBehavioral Diagnostics

Kollol Pal, CEO, Mnemosyne Pharmaceuticals

Derek Small, CEO, Naurex

Stanley Shapiro, CEO,

 4:30 Traumatic Injury: Stroke, TBI and SCI
  Drugs and devices are on the horizon to improve outcomes of patients with acute traumatic injury. Novel strategies allow some to succeed where many have failed.

Session Chair: Rob Abrams, Operating Partner, Sanderling Ventures  and CEO Pulsar Vascular

Brian Leuthner, CEO, Edge Therapeutics

Kent Pryor, COO,
ZZ Biotech

Emily Stein, CEO, Sevident

Remis Bistras, CEO, Vittamed
Networking Reception
  Friday May 24, 2013
Continental Breakfast & Registration
 8:00 Partnering and Licensing in Neurotech Panel
  Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions?  With big pharma paying more attention to neurodiagnostics, what kinds of deals and partnerships can we expect in 2013 and 2014?

Moderator: Christine de los Reyes, VP Strategic Planning and Business Development, Alopexx

David Baker, Vice President, Innovation & Imagination - Behavioral Health, Shire Pharmaceuticals

Jeffrey Erb, Sr. Director of BD, Alliances and IP Portfolio Management, Medtronic Neuromodulation

Jason Kralic, Head, Neurosciences Business Development, GlaxoSmithKline

Jay Kranzler, Global Head, External R&D Innovation: Neuroscience, Pain, & Sensory Disorders, Pfizer

9:15 Networking and Refreshment Break
9:45 Frontiers in Neurotechnology
  In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets including asthma, migraine, psychiatry, and epilepsy. Closed loop systems create the promise of reduced side effects and more targeted treatment.  New technology is yielding benefits in neurodiagnostics. Software solutions are tackling neuropsychiatric markets. Don't miss this preview of next generation products and companies.

Session Chair: Roger Quy, General Partner, Technology Partners

Alexander Bystritsky, Founder and CEO, Brainsonix

JP Errico, CEO, Electrocore

Ronen Gadot, CEO, Elminda

Eddie Martucci, Director of R&D, Akili Interactive, Sr. Associate Puretech Ventures

Eric Lynch, CEO, Sound Pharmaceuticals 

11:00 Strategies in CNS Drug and Device Development
  Intelligent trial design, fundraising, and business development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement. Case studies will demonstrate lessons learned in Alzheimer's, Parkinson's, depression, pain and more.

Session Chair: Liam Ratcliffe, General Partner, New Leaf Venture Partners

Simone Braggio, Director, Drug Design and Discovery, Aptuit

Samer Kaba, Vice President Neuroscience, Medpace

Kevin Wasserstein, Affiliate Director, Versant Ventures and Founder, MentorCatalyst

12:00 Lunch 
1:30 Movement Disorders: Parkinson's, ALS and more
  Exciting developments are in the pipeline for slowing progression of some of the most vexing neurological conditions like Parkinson's, ALS, and Duchenne muscular dystrophy.  What is the latest science behind new targets?  What is in the pipeline for symptomatic and disease modifying treatments? Can devices pick up where pharmaceuticals leave off?

Steve Mickel, Director Commercial Development, Neuroscience, AbbVie

RJ Tesi, CEO, 
FPRT Biosciences

Jonathan Solomon, CEO, Neurophage

Winston Ko, CEO, Genervon

Geoffrey Thrope, Founder and Managing Director, NDI Medical

2:30 NIO BRAIN Initiative Discussion  (All are welcome)
  An overview and participant discussion of current and future congressional, FDA, and CMS initiatives to advance neurotech.  How can translational and commercial neuroscience benefit from the BRAIN initiative. 

Zack Lynch, Executive Director, Neurotechnology Industry Organization

John Reppas, Director of Public Policy, Neurotechnology Industry Organization

Daniel Ritter, Partner, K&L Gates, NIO Public Policy Counsel

Suzan Onel, Partner, K&L Gates, NIO Regulatory Counsel

3:00 Refreshments and One -to- One Networking Time
 5:30 Conference Concludes



Contact Information